Choosing the Best Treatment for Esophageal Cancer

Criteria for Selecting the Best Multimodal Therapy
  • A. H. Hölscher
  • E. Bollschweiler
Conference paper
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 196)


The best multimodal therapy in esophageal cancer comprises neoadjuvant radiochemotherapy in patients with adenocarcinoma or squamous cell carcinoma whereas neoadjuvant chemotherapy is only appropriate for patients with adenocarcinoma. However, the 2-year survival benefit by this induction therapy compared to surgery alone is only 5–9 %. Targeted drugs seem to be promising in order to improve the response rate. The choice of the best multimodal therapy by response prediction seems only to be possible in patients during chemotherapy for adenocarcinoma, whereas during neoadjuvant radiochemotherapy a response prediction by FDG–PET is not possible. The principle item of multimodal therapy is still transthoracic en bloc esophagectomy which should be performed in high volume centers in order to guarantee stable and good results.


Squamous Cell Carcinoma Esophageal Cancer Induction Therapy Esophageal Carcinoma Resected Lymph Node 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Arnott SJ, Duncan W, Kerr GR, Walbaum PR, Cameron E, Jack WJ, Mackillop WJ (1992) Low dose preoperative radiotherapy for carcinoma of the oesophagus: results of a randomized clinical trial. Radiother Oncol 24:108–113PubMedCrossRefGoogle Scholar
  2. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697PubMedCrossRefGoogle Scholar
  3. Bollschweiler E, Metzger R, Drebber U, Baldus S, Vallböhmer D, Kocher M, Hölscher AH (2009) Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol 20:231–238PubMedCrossRefGoogle Scholar
  4. Bollschweiler E, Baldus S, Schroder W, Schneider P, Hölscher A (2006) Staging of esophageal carcinoma: length of tumor and number of involved regional lymph nodes. Are these independent prognostic factors? J Surg Oncol 94:355–363PubMedCrossRefGoogle Scholar
  5. Bollschweiler E, Besch S, Drebber U, Schröder W, Mönig SP, Vallböhmer D, Baldus SE, Metzger R, Hölscher AH (2010) Influence of neoadjuvant chemoradiation on the number and size of analyzed lymph nodes in esophageal cancer. Ann Surg Oncol 17:3187–3194PubMedCrossRefGoogle Scholar
  6. Burmeister TH, Thomas JM, Burmeister EA, Walpole ET, Harvey JA, Thomson DB, Barbour AP, Gotley DC, Smithers BM (2011) Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer 47:354–360PubMedCrossRefGoogle Scholar
  7. Fiorica F, Di Bona D, Schepis F et al (2004) Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 53:925–930PubMedCrossRefGoogle Scholar
  8. Fok M, Sham JS, Choy D, Cheng SW, Wong J (1993) Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. Surgery 113(2):138–147PubMedGoogle Scholar
  9. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in esophageal carcinoma: a meta-analysis. Lancet Oncol 8:226–234PubMedCrossRefGoogle Scholar
  10. Gibson MK, Catalano PJ, Kleinberg L (2010) E2205: a phase II study to measure response rate and toxicity of neoadjuvant chemoradiotherapy (CRT) with oxaliplatin (OX) and infusional 5-flourouracil (5-FU) plus cetuximab (C) followed by postoperative docetaxel (DT) and C in patients with operable adenocarcinoma of the esophagus. J Clin Oncol 28:15s (abstract 4064)Google Scholar
  11. Gignoux M, Roussel A, Paillot B, Gillet M, Schlag P, Dalesio O, Buyse M, Duez N (1987) The value of preoperative radiotherapy in esophageal cancer: results of a study of the E.O.R.T.C. World J Surg 11:426–432PubMedCrossRefGoogle Scholar
  12. Greer SE, Goodney PP, Sutton JE, Birkmeyer JD (2005) Neoadjuvant chemoradiation for esophageal carcinoma: a meta-analysis. Surgery 137:172–179PubMedCrossRefGoogle Scholar
  13. Hölscher AH, Bollschweiler E, Schröder W, Metzger R, Gutschow C, Drebber U (2011) Prognostic impact of upper, middle, and lower third mucosal or submucosal infiltration in early esophageal cancer. Ann Surg 254(5):802–807 (discussion 807–808)PubMedCrossRefGoogle Scholar
  14. Jin HL, Zhu H, Ling TS, Zhang HJ, Shi RH (2009) Neoadjuvant chemoradiotherapy for respectable esophageal carcinoma: a meta-analysis. World J Gastroenterol 15:5983–5991PubMedCrossRefGoogle Scholar
  15. Kaklamanos IG, Walker GR, Ferry K, Franceschi D, Livingstone AS (2003) Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol 10:754–761PubMedCrossRefGoogle Scholar
  16. Launois B, Delarue D, Campion JP, Kerbaol M (1981) Perioperative radiotherapy for carcinoma of the esophagus. Surg Gynecol Obstet 153:690–692PubMedGoogle Scholar
  17. Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang YJ, Clark JW, Solomon BJ, Lafrate AJ (2011) MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 29(36):4803–4810PubMedCrossRefGoogle Scholar
  18. Lordick FL, Hölscher AH (2007) Chirurgische und internistische Diagnostik und Therapie des Oesophaguskarzinom. Gastroenterologie up 2 date 2007. 3:293–319Google Scholar
  19. Malthaner R, Fenlon D (2003) Preoperative chemotherapy for resectable thoracic esophageal cancer the cochrane database of systematic reviews 4: CD001556. DOI:  10.1002/14651858.CD001556
  20. Malthaner R, Wong R, Rumble R, Zuraw L (2004) Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med 2:35PubMedCrossRefGoogle Scholar
  21. Nygard K, Hagen S, Hansen HS (1992) Preoperative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized multicenter study of preoperative radiotherapy and chemotherapy. The second scandinavian trial in esophageal cancer. World J Surg 16:1104–1109CrossRefGoogle Scholar
  22. Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Focken P, van Dekken H, Ten Kate FJ, Obertop H, Tilanus HW, van Lanschot JJ (2007) Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus. Five-year survival of a randomized clinical trial. Ann Surg 246:992–1001PubMedCrossRefGoogle Scholar
  23. Peyre C, Hagen J, De Meester S, Altorki N, Ancona E, Griffin S, Hölscher A, Lerut T, Law S, Rice T, Ruol A, van Lanschot J, Wong J, De Meester T (2008) The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg 248:549–556PubMedCrossRefGoogle Scholar
  24. Ruhstaller T, Pless M, Dietrich D, Kranzbuehler H, von Moos R, Moosmann P, Montemurro M, Schneider PM, Rauch D, Gautschi O, Mingrone W, Widmer L, Inauen R, Brauchli P, Hess V (2011) Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). J Clin Oncol 29:626–639PubMedCrossRefGoogle Scholar
  25. Ruol A, Rizzetto C, Castoro C, Cagol M, Alfieri R, Zanchettin G, Cavallin F, Michieletto S, Da Dalt G, Sileni VC, Corti L, Mantoan S, Zaninotto G, Ancona E (2010) Interval between neoadjuvant chemoradiotherapy and surgery for surgery for squamous cell cancer of the thoracic esophagus. Ann Surg 252:788–796PubMedCrossRefGoogle Scholar
  26. Schneider PM, Metzger R, Schaefer H, Baumgarten F, Vallbohmer D, Brabender J, Wolfgarten E, Bollschweiler E, Baldus SE, Dienes HP, Hoelscher AH (2008) Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg 248:902–908PubMedCrossRefGoogle Scholar
  27. Semrau R, Vallböhmer D, Hölscher AH, Müller RP (2009) Neoadjuvant therapy of adenocarcinomas of the upper gastrointestinal tract. Status of radiotherapy. Chirurg 80:1035–1041PubMedCrossRefGoogle Scholar
  28. Sjoquist KM, Burmeister BH, Smithers BM et al (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12:681–692PubMedCrossRefGoogle Scholar
  29. Stahl M, Walz MK, Stuschke M et al (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27:851–856PubMedCrossRefGoogle Scholar
  30. Urschel JD, Vasan H, Blewett CJ (2002) A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg 183:274–279PubMedCrossRefGoogle Scholar
  31. Urschel JD, Vasan H (2003) A meta-analysis of randomised controlled trials that compared neoadjuvant chemoradiation and surgery alone for resectable esophageal cancer. Am J Surg 185:538–543PubMedCrossRefGoogle Scholar
  32. Vallböhmer D, Hölscher AH, DeMeester S, DeMeester T, Salo J, Peters J, Lerut T, Swisher SG, Schröder W, Bollschweiler E, Hofstetter W (2010) A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer. Ann Surg 252:744–749PubMedCrossRefGoogle Scholar
  33. Vallböhmer D, Hölscher AH, Dietlein M, Bollschweiler E, Baldus SE, Mönig SP, Metzger R, Schicha H, Schmidt M (2009) [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg 250:888–894PubMedCrossRefGoogle Scholar
  34. van Heijl M, Omloo JM, van Berge Henegouwen MI, Hoekstra OS, Boellaard R, Bossuyt PM, Busch OR, Tilanus HW, Hulshof MC, van der Gaast A, Nieuwenhuijzen GA, Bonenkamp HJ, Plukker JT, Cuesta MA, Ten Kate FJ, Pruim J, van Dekken H, Bergman JJ, Sloof GW, van Lanschot JJ (2011) Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg 253:56–63PubMedCrossRefGoogle Scholar
  35. Wang M, Gu XZ, Yin WB, Huang GJ, Wang LJ, Zhang DW (1989) Randomized clinical trial on the combination of perioperative irradiation and surgery in the treatment of esophageal carcinoma: report on 206 patients. Int J Radiat Oncol Biol Phys 16:325–327PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Department of General, Visceral and Cancer SurgeryUniversity of CologneKölnGermany

Personalised recommendations